Research Article
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Table 2
Mutation types of RAS/BRAF detected in 76 patients.
| Gene | Mutation | Tissue | Plasma | Synchronous group | Metachronous group | Total | Synchronous group | Metachronous group | Total |
| KRAS | G12A, G12C, G12D, G12V, G13D, G13S | 26.32% (5/19) | 45.24% (19/42) | 39.34% (24/61) | 35.42% (17/48) | 14.29% (4/28) | 27.63% (21/76) | KRAS | Q61H, Q61K | 5.26% (1/19) | 0% (0/42) | 1.64% (1/61) | 0% (0/48) | 10.71% (3/28) | 3.95% (3/76) | KRAS | A146T | 0% (0/19) | 0% (0/42) | 0% (0/61) | 0% (0/48) | 3.57% (1/28) | 1.32% (1/76) | NRAS | G12V, G12D | 5.88% (1/17) | 0% (0/39) | 1.79% (1/56) | 2.08% (1/48) | 0% (0/28) | 1.32% (1/76) | NRAS | Q61R, Q61K | 0% (0/17) | 7.69% (3/39) | 5.36% (3/56) | 2.08% (1/48) | 0% (0/28) | 1.32% (1/76) | BRAF | Y472F, P403fs | 0% (0/18) | 0% (0/40) | 0% (0/58) | 2.08% (1/48) | 3.57% (1/28) | 2.63% (2/76) | HRAS | G12D | / | / | / | 2.08% (1/48) | 0% (0/28) | 1.32% (1/76) | HRAS | P167fs | / | / | / | 2.08% (1/48) | 3.57% (1/28) | 2.63% (2/76) |
|
|